Management of Nephritic Syndrome
Nephritic syndrome requires immediate diagnostic kidney biopsy to guide immunosuppressive therapy, combined with aggressive blood pressure control targeting <120 mmHg systolic using ACE inhibitors or ARBs as first-line agents, while addressing the underlying glomerulonephritis based on histopathologic classification.
Initial Diagnostic Approach
Kidney biopsy is indispensable when nephritic syndrome presents with hematuria, proteinuria (≥0.5 g/24h), and declining renal function 1. Clinical and serological tests cannot accurately predict histopathology, making biopsy essential for directing treatment 1. The biopsy should be classified using the ISN/RPS 2003 system with assessment of active and chronic changes 1.
Blood Pressure and Proteinuria Management
Immediate Targets
- Systolic blood pressure <120 mmHg using standardized office measurement 2
- Start ACE inhibitor or ARB immediately, uptitrating to maximally tolerated dose 2
- Do not delay RAS blockade even if immunosuppression is planned 2
Adjunctive Measures
- Restrict dietary sodium to <2.0 g/day 2
- Use potassium-wasting diuretics if hyperkalemia develops to maintain RAS blockade 2
- Add mineralocorticoid receptor antagonists for refractory proteinuria (monitor potassium closely) 2
Common pitfall: Waiting to start ACE inhibitors/ARBs until after immunosuppression begins. Start immediately as these reduce proteinuria and slow progression independent of immunosuppression 1.
Disease-Specific Immunosuppressive Treatment
For Proliferative Lupus Nephritis (Class III/IV)
Initial induction therapy (choose one) 3:
- Mycophenolate mofetil 2-3 g/day (preferred for better efficacy/toxicity ratio) PLUS
- Glucocorticoids: IV methylprednisolone 500-750 mg for 3 consecutive days, then oral prednisone 0.3-0.5 mg/kg/day 3
Alternative for severe disease with adverse prognostic factors (rapidly declining GFR, cellular crescents, fibrinoid necrosis):
- Low-dose IV cyclophosphamide 500 mg every 2 weeks × 6 doses 3
- OR MMF/tacrolimus combination for nephrotic-range proteinuria 3
Maintenance therapy (after 6 months induction) 1, 3:
- Continue MMF at lower dose (2 g/day) OR azathioprine 2 mg/kg/day
- For at least 3 years with low-dose prednisone (5-7.5 mg/day) 1
- Taper glucocorticoids to <7.5 mg/day by 4-6 months 3
For Membranous Nephropathy (Class V)
If proteinuria >1 g/24h despite RAS blockade 3:
- MMF 3 g/day for 6 months PLUS prednisone 0.5 mg/kg/day (preferred)
- Alternatives: cyclophosphamide, calcineurin inhibitors (cyclosporine/tacrolimus), or rituximab 1, 3
For Post-Infectious or IgA Nephropathy
Conservative management first 4:
- Optimize blood pressure control with RAS blockade
- Observe for 6 months before considering immunosuppression 5
- Reserve immunosuppression for progressive disease with declining GFR or crescentic features
Treatment Response Monitoring
Target Goals 1, 3
- Complete response: Proteinuria <0.5-0.7 g/24h with normal/near-normal GFR by 12 months
- Partial response: ≥50% reduction in proteinuria to subnephrotic levels by 6-12 months
Monitoring Schedule 1
- Every 2-4 weeks for first 2-4 months after diagnosis
- Then every 3-6 months lifelong
- At each visit: serum creatinine, eGFR, proteinuria, urinary sediment, serum albumin, C3/C4, anti-dsDNA (if lupus)
Management of Refractory Disease
If no response by 6-12 months 1, 3:
- Switch from MMF to cyclophosphamide or vice versa
- Add rituximab for treatment failures
- Consider repeat biopsy if GFR worsening or persistent proteinuria beyond 1 year 1
Critical point: Wait at least 6 months after completing initial regimen before declaring treatment failure, unless GFR is rapidly deteriorating 5.
Essential Adjunctive Therapies
Thromboembolism Prevention 1
- Anticoagulation if serum albumin <2.0 g/L, especially with antiphospholipid antibodies
- Low-dose aspirin for arterial thrombosis prophylaxis in high-risk patients 6
Cardiovascular Risk Reduction 1, 2
- Statin therapy targeting LDL <100 mg/dL (2.58 mmol/L)
- Hydroxychloroquine in lupus nephritis to reduce renal flares 1
Infection Prevention 1
- Non-live vaccines (pneumococcal, influenza)
- Calcium and vitamin D supplementation
Key Pitfalls to Avoid
- Delaying kidney biopsy: Never treat nephritic syndrome empirically without histologic diagnosis 1
- Excessive glucocorticoid exposure: Taper to ≤7.5 mg/day by 6 months; prolonged high doses increase infection and cardiovascular risk 3
- Premature treatment escalation: Allow 6-12 months for response before switching regimens 5
- Ignoring blood pressure: Hypertension accelerates progression independent of immunosuppression 2
- Stopping maintenance therapy too early: Continue for minimum 3 years to prevent relapse 1, 3